Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team

J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244.

Abstract

The effect of baseline drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in zidovudine-experienced persons infected with human immunodeficiency virus type 1 (HIV-1). Presence of the K70R mutation was associated with significantly higher plasma HIV-1 RNA levels at baseline. However, presence of resistance mutations did not affect the increase in plasma HIV-1 RNA during a 5-week drug washout, nor was there any effect on first-phase virus decay rates after initiation of therapy or on the probability of having plasma HIV-1 RNA levels <100 copies/mL at week 48. Polymorphisms at protease codons 10, 36, and 71 were associated with significantly faster second-phase decay rates. Suppression of plasma HIV-1 RNA despite presence of zidovudine resistance mutations implies that the presence of these mutations does not preclude a durable response to treatment with a potent 3-drug regimen.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Microbial / genetics
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease / genetics
  • HIV Protease Inhibitors / therapeutic use
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • Humans
  • Lamivudine / therapeutic use
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Mutation
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / therapeutic use
  • Viral Load
  • Zidovudine / pharmacology*
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • HIV Reverse Transcriptase
  • HIV Protease
  • Ritonavir

Associated data

  • GENBANK/AF198391
  • GENBANK/AF198392
  • GENBANK/AF198393
  • GENBANK/AF198394
  • GENBANK/AF198395
  • GENBANK/AF198396
  • GENBANK/AF198397
  • GENBANK/AF198398
  • GENBANK/AF198399
  • GENBANK/AF198400
  • GENBANK/AF198401
  • GENBANK/AF198402
  • GENBANK/AF198403
  • GENBANK/AF198404
  • GENBANK/AF198405
  • GENBANK/AF198406
  • GENBANK/AF198407
  • GENBANK/AF198408
  • GENBANK/AF198409
  • GENBANK/AF198410
  • GENBANK/AF198411
  • GENBANK/AF198412
  • GENBANK/AF198413
  • GENBANK/AF198414
  • GENBANK/AF198415
  • GENBANK/AF198416
  • GENBANK/AF198417
  • GENBANK/AF198418
  • GENBANK/AF198419
  • GENBANK/AF198420